Last updated: February 14, 2026
What is NDC 49502-0250?
The National Drug Code (NDC) 49502-0250 designates Venclexta (venetoclax), manufactured by AbbVie. It is an oral BCL-2 inhibitor approved for hematologic malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML).
Market Landscape
Sales Performance
- 2019-2022: Sales of Venclexta have grown significantly. In 2022, it generated approximately $1.2 billion in U.S. sales, reflecting a compound annual growth rate (CAGR) around 33% during this period.
- Key Indications: CLL/SLL accounts for over 70% of revenue, with AML sales increasing as expanding approvals and label updates include this indication.
- Market Share: Among targeted hematopoietic malignancy drugs, Venclexta ranks third behind first-line therapies like Gleevec and Imbruvica, but it is gaining market share due to favorable efficacy profiles.
Competitive Landscape
- Major competitors include Gilead's Venetoclax-based combinations (e.g., Venclexta + Rituximab), AstraZeneca's Calquence, and newer entrants like BeiGene's Brukinsa.
- Expansion of indications, including newly approved uses in AML and combination regimens, boost the drug's growth prospects.
Pricing Overview
Current U.S. Wholesale Acquisition Cost (WAC)
- The standard daily dose is 400 mg, administered typically 30 days per month.
- Average monthly price: Approximately $18,000, translating to $216,000 annually (per patient).
Pricing Trends
- Prices have remained stable since initial launch in 2016 but face potential pressure from biosimilar or generic competition in the next 5-7 years.
- The U.S. price remains significantly higher than international markets, where affordability measures, rebates, and pricing controls lower actual consumer costs.
Market Size and Revenue Forecasts
Addressable Patient Population
- Estimated 30,000 patients globally receiving venetoclax annually for approved indications.
- The U.S. accounts for about 60% of total sales due to higher prevalence and access.
Revenue Projections
| Year |
Global Sales (USD Billions) |
U.S. Share |
Notes |
| 2023 |
1.3 |
0.78 |
Expected moderate growth as indications expand |
| 2024 |
1.5 |
0.9 |
Increased adoption in AML |
| 2025 |
1.7 |
1.02 |
Potential for new combination approvals |
| 2026 |
1.9 |
1.14 |
Possible biosimilar entry pressures |
Market Drivers
- Expansion of indications, especially in AML.
- Improving patient survival rates.
- Growing use in combination therapies may increase demand.
- Competition may cap pricing growth after 2024.
Price Projection Considerations
- Premium Pricing: Current prices reflect efficacy in difficult-to-treat hematologic cancers.
- Competition Impact: Entry of biosimilars or alternative therapies capable of reducing prices.
- Reimbursement Policies: Changes in insurer reimbursement strategies could pressure list prices or shift toward value-based pricing models.
- Manufacturing Costs: Stable, with no anticipated significant reductions in the short term.
Risks and Opportunities
Risks
- Biosimilar or generic entry around 2028-2030 could reduce prices by 30-50%.
- Regulatory changes or increased price scrutiny, especially in public markets.
- Slow adoption in new indications or markets.
Opportunities
- Broader indication approval, including frontline AML.
- Combination therapies with newly approved agents.
- Biomarker-driven patient selection improving treatment outcomes.
Key Takeaways
- NDC 49502-0250 (Venclexta) has experienced consistent revenue growth driven by expanding indications and clinical adoption.
- U.S. pricing remains high at roughly $216,000 annually per patient but is subject to downward pressure from biosimilars and reimbursement reforms.
- Market forecasts predict revenues reaching approximately $1.9 billion globally by 2026, with the U.S. maintaining the majority share.
- Price stability is expected in the short-term, with pressure emerging from biosimilars in the late-2020s.
Frequently Asked Questions
1. When could biosimilars for venetoclax enter the market?
Biosimilars are typically approved 8-12 years after the original drug. For venetoclax, this suggests biosimilar entry around 2028-2030, potentially leading to price reductions.
2. How are new indications affecting the drug’s market?
New approvals, especially in AML, broaden the patient base, increasing sales. The expansion could also justify maintaining higher prices due to unmet medical needs.
3. What factors influence pricing in different markets?
Pricing depends on reimbursement policies, local regulations, competitive landscape, and negotiated discounts with payers. International markets often have lower prices due to government regulation.
4. What is the expected impact of combination therapies?
Combining venetoclax with other agents may enhance efficacy, driving demand and potentially allowing for premium pricing for multi-drug regimens.
5. How might regulatory or market access policies evolve?
Increased scrutiny on drug prices and emphasis on value-based care could lead to tighter pricing controls and expanded use of cost-effectiveness assessments.
References
- IQVIA prices and sales data [1].
- FDA approval history and label updates [2].
- Market share and competitive landscape reports [3].
- Industry forecasts and strategic reports (Evaluate Pharma, 2023) [4].
[1] IQVIA. "Pharmaceutical Market Reports," 2022.
[2] U.S. Food and Drug Administration. "Venclexta (venetoclax) approval and label information," 2016.
[3] Symphony Health. "Cancer drug competitive landscape," 2023.
[4] Evaluate Pharma. "Global Oncology Market Forecasts," 2023.
